Treatment paradigms have shifted from non-steroid anti-inflammatory drugs for an initial stage of RA to the administration of anti-TNF-α antibodies or JNK inhibitors for a late stage of RA (Demoruelle and Deane, 2012; Smolen et al., 2017). Here, MAPK8 is linked to rheumatoid arthritis.